Table 2.
Investigational therapies in R/R cHL
| Agent | Study design | Median age (range), years | Total (N) | Prior AHCT (n) | ORR% (CR%) | Median PFS/EFS (mo) | Reference |
|---|---|---|---|---|---|---|---|
| Cami | I* | 38 (31-53) | 57 | NR | 75 (44) | NR | Hamadani et al22 |
| Cami | II | 36 (20-74) | 51 | 31 | 83 (38) | NR | Herrera et al23 |
| Everolimus | II | 32 (19-77) | 57 | 38 | 46 (9) | 8 | Johnston et al25 |
| Lenalidomide | II | 37 (18–74) | 15 | 10 | 13 | NR | Kuruvilla et al28 |
| Lenalidomide | II | 38 (20–83) | 42 | 31 | 30 | 8.2 | Fehniger et al29 |
| Vorinostat | II | 42 (20-71) | 25 | 11 | 4 | 7.2 | Kirschbaum et al32 |
| Panobinostat | II | 32 (18-75) | 129 | 129 | 27 (4) | 6.9 | Younes et al33 |
| Idelalisib | II | 42 (21-80) | 25 | 18 | 20 (4) | 2.3 | Gopal et al51 |
| Ibrutinib† | Retrosp | 35 (26-72) | 7 | 5 | 57 (43) | NA | Badar et al52 |
*
Data shown for 30 µg/kg and 45 µg/kg cohorts.
†
A clinical trial is ongoing investigating the role of ibrutinib in R/R cHL (NCT02824029).
NA, not applicable; NR, not reported; Retrosp, retrospective.